Abstract
Key Points Atrial fibrillation is a co‐morbidity for PCI patients that may complicate risk‐benefit decisions for antithrombotic therapy. Recently developed PRECISE‐DAPT score may be useful in judging the bleeding risk of atrial fibrillation patients undergoing PCI. Optimal tools to understand bleeding risk from both pharmacologic and device choices continue to be a need in the PCI population.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
